FORM OF EXCHANGE AND CONSENT AGREEMENTExchange and Consent Agreement • November 14th, 2016 • Tetralogic Pharmaceuticals Corp • Pharmaceutical preparations • New York
WHEREAS, the Company has agreed to sell substantially all of its assets relating to the birinapant and SHP-141 (remetinostat) lead molecules to Medivir AB, a company organized under the laws of Sweden (such transaction, the “Asset Purchase”), pursuant to the terms and conditions of that certain asset purchase agreement by and among the Company, its wholly-owned subsidiary TetraLogic Research and Development Corporation and Medivir AB, dated as of November 1, 2016 (the “APA”);
